Studies conducted in seven European countries, Spain, France, Italy, Hungary, Romania, Ireland, and Portugal, confirm the effectiveness of the 2009 – 2010 dose of the H1N1 vaccine. This study, which was conducted by the European Center for Disease Control, is perhaps a positive sign for the 2010 – 2011. The study at least points to the effectiveness of the 2009 strain that was included in the 2010 – 2011 trivalent vaccine.
The findings found that doses of the H1N1 influenza vaccine were most effective in healthy adults, especially those under the age of 65. Participating individuals were given a throat swab done within a week of a person having shown showing signs of having contracted the H1N1 flu. If the individual had received the vaccine at least two weeks before contracting the virus, they were considered vaccinated. If they had not been vaccinated, or if their vaccination fell within those two weeks of contracting the virus, they were not considered vaccinated.
The overall statistics of the study proved that the vaccine was most effective when having been administered at least two weeks prior to having come in contact with the virus. The study also broke down statistics by age group, and the overall effectiveness of the vaccine in comparison to the exact number of days the vaccine was administered prior to the onset of H1N1 flu like symptoms. While the study did find positive results, it also proved the effectiveness of the vaccine when compared to the general 2009-2010 seasonal vaccine. As opposed to the H1N1 vaccine, the seasonal vaccine did not appear to provide any protection against the virus.
Of course, as many people are aware, even though the drug was effective, it was hindered by its low availability. The vaccine was not readily available; thus limiting its ability to be effective.